查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947951

PNH药物市场：药物类别、给药途径、通路、最终用户、治疗阶段、年龄层、全球预测（2026-2032年）

Drugs for PNH Market by Drug Class, Route Of Administration, Distribution Channel, End User, Line Of Therapy, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，阵发性夜间血红蛋白尿症 (PNH) 治疗市场价值将达到 19.2 亿美元，到 2026 年将增长至 20.6 亿美元，年复合增长率为 9.02%，到 2032 年将达到 35.1 亿美元。

关键市场统计数据
基准年 2025 19.2亿美元
预计年份：2026年 20.6亿美元
预测年份 2032 35.1亿美元
复合年增长率 (%) 9.02%

本书全面介绍了阵发性睡眠性血尿症治疗领域不断发展的临床和医疗服务环境，并着重于患者预后。

阵发性睡眠性血尿症是一种罕见的、严重影响患者生活的血液疾病，其特征是补体介导的红血球破坏、血栓症风险和慢性溶血。对补体生物学分子机制的深入了解，促成了标靶治疗药物的研发，彻底改变了疾病的治疗方式，推动了治疗策略从反覆输血和支持治疗转向针对特定补体通路的抑制。这种治疗方法的转变凸显了不断完善的治疗标准的重要性，治疗方法的选择、给药途径和患者意愿越来越决定着患者的长期预后和生活品质。

对治疗机制、给药方法和护理模式中模式转移创新进行观点的相关人员分析，这些创新正在重塑阵发性睡眠性血红蛋白尿症（PNH）的治疗。

过去几年，阵发性睡眠性血红蛋白尿症 (PNH) 的治疗格局发生了变革性变化，作用机制不断创新，给药途径日益多样化，并且更加註重以患者为中心的护理。抑制近端和远端补体活化的治疗方法的出现，拓展了治疗选择，使临床医生能够根据溶血控制、输血依赖、血栓风险和合併症等因素制定个体化治疗方法。这些科学进步与给药方式的创新相辅相成，例如皮下製剂，这些创新减轻了临床负担，并支持患者自我给药模式，从而提高了便利性和依从性。

评估2025年美国潜在关税变化对阵发性睡眠性血红蛋白尿症（PNH）药物供应链、生产本地化、价格波动和患者用药的影响

2025年公布的潜在关税和贸易政策调整将产生策略性变数，影响生物製药及其活性成分的供应、成本结构和供应链韧性。如果新关税影响进口原料、一次性组件或成品生物製剂，製造商可能面临生产成本上涨的压力。这些成本波动可能会影响与支付方和医疗服务提供方的合约行为，促使重新谈判定价条款，并加速关于风险分担和按绩效付费合约的讨论。

策略性細項分析揭示了药物类别、给药途径、分销管道、临床环境、治疗方案和年龄组如何驱动临床和商业策略的差异化。

详细的市场细分框架揭示了药物类别、给药途径、分销管道、终端用户类型、治疗方案和年龄组等因素的不同市场动态，这些因素共同影响着商业和临床策略。在各类药物中，市场可区分近端补体抑制剂和末端补体抑制剂。前者着重于抑制C5上游活化的药物，而后者则包括已上市的靶向C5的单株抗体，这些抗体的给药间隔和输注要求各不相同。临床医师会考虑这些作用机制的差异以及患者的个别特征，以指南药物转换或剂量增加的决策。

对美洲、欧洲、中东和非洲以及亚太地区PNH（阵发性夜间血红蛋白尿症）治疗普及的监管预期、支付方趋势和治疗模式进行区域比较分析

区域趋势对监管路径、报销框架和医疗服务模式有着深远的影响，进而塑造治疗方法的引进和应用。在美洲，监管核准和已建立的专科医疗网络促进了新型生物製药的快速普及，而支付方的谈判则往往侧重于价值论证和准入管理协议。该地区居家照护和专科药房解决方案的使用也在不断增加，这减轻了医疗机构的负担，提高了患者的便利性，并且正在建立专家中心来支持复杂病例的管理。

对企业策略（临床差异化、生产韧性和服务伙伴关係）如何决定PNH治疗领域的竞争地位进行了深入评估。

在阵发性睡眠性血红素尿症（PNH）领域，各公司的策略体现了在临床差异化、给药方式创新、生产规模和下游支援服务等方面的不同重点。成熟的C5标靶疗法开发商利用长期安全性数据和优化的给药间隔来维持医疗系统的信任，而专注于近端补体抑制的新兴参与企业则强调溶血控制方面的机制优势和皮下给药的便利性。这种差异化为那些能够展现卓越治疗效果并显着改善患者用药体验的平台创造了明显的机会。

针对开发人员和商业领袖的具体且全面的建议，旨在加速PNH治疗领域的应用，降低风险，并保障病患的治疗权益。

为确保在阵发性睡眠性血红蛋白尿症 (PNH) 领域持续获得认可，产业领导者应优先考虑整合临床开发、供应链韧性和支付方合作的策略。首先，应调整临床项目，以产生强调疗效比较、长期安全性和患者报告结局的证据，并直接符合支付方和临床医生的决策标准。同时，投资真实世界证据平台可以增强价值提案，并缩短临床实务与药品目录决策流程之间的回馈週期。

对混合调查方法进行透明的解释，该方法结合了相关人员访谈、文献综述和情境分析，以支持切实可行的策略结论。

本分析结合了第一手和第二手研究，全面涵盖了临床、商业性和政策方面。第一手研究包括对临床专家、支付方以及输液中心和专科药房的营运负责人进行结构化访谈，并辅以製药公司揭露的资讯和监管文件。第二手研究引用了同行评审文献、临床试验註册资讯和已发布的监管决策，以阐明治疗方案、安全性考量和适应症的差异。

一份权威的综合分析报告，重点阐述了将治疗创新转化为持续的患者可及性和系统性价值所需的关键策略重点。

目前阵发性睡眠性血红蛋白尿症 (PNH) 的治疗环境呈现出显着的临床进展、不断演变的医疗服务模式以及日益复杂的商业性和政策特征，这要求我们采取灵活、循证的策略，并全面考虑这些因素。补体抑製作用机制的多样化和更人性化的给药方式的出现，虽然改善了临床选择，但也需要各方协作，共同推进循证实践、与支付方谈判以及服务模式的重塑。能够将临床差异化、卓越营运和符合支付方利益的价值论证相结合的相关人员，将更有可能取得成功。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按药物类别分類的 PNH 药物市场

  • 近端补体抑制剂
  • 末端补体抑制剂
    • Eculizumab
    • Ravulizumab

9. 按给药途径分類的 PNH 药物市场

  • 静脉注射
  • 皮下注射

10. 按分销管道分類的 PNH 药物市场

  • 居家输液
  • 医院药房
  • 专科药房

第十一章 按最终用户分類的 PNH 药物市场

  • 诊所
  • 居家照护
  • 医院

12. 按治疗阶段分類的 PNH 药物市场

  • 一线治疗
  • 二级治疗

13. 按年龄组别分類的 PNH 药物市场

  • 成人版
  • 儿童
  • 老年人

14. 按地区分類的PNH药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 按组别分類的 PNH 药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国PNH药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国阵发性睡眠性血红素尿症（PNH）药物市场

第十八章：中国的阵发性睡眠性血红素尿症（PNH）药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ra Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Swedish Orphan Biovitrum AB
  • UCB SA
Product Code: MRR-4F7A6D4FB6A1

The Drugs for PNH Market was valued at USD 1.92 billion in 2025 and is projected to grow to USD 2.06 billion in 2026, with a CAGR of 9.02%, reaching USD 3.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.92 billion
Estimated Year [2026] USD 2.06 billion
Forecast Year [2032] USD 3.51 billion
CAGR (%) 9.02%

Comprehensive introduction to the evolving clinical and care delivery landscape for paroxysmal nocturnal hemoglobinuria therapies with focus on patient outcomes

Paroxysmal nocturnal hemoglobinuria is a rare, life-altering hematologic disorder driven by complement-mediated red blood cell destruction, thrombosis risk, and chronic hemolysis. Advances in molecular understanding of complement biology have translated into targeted therapeutics that fundamentally alter disease management, shifting care from repeated transfusions and supportive measures toward pathway-specific inhibition. This therapeutic transition underscores an evolving standard of care in which treatment choice, route of administration, and patient preference increasingly determine long-term outcomes and quality of life.

Against this clinical backdrop, stakeholders must navigate a complex interplay of clinical efficacy, administration logistics, payer negotiation, and patient support needs. Recent approvals and label expansions have broadened treatment options, introducing varying pharmacologic mechanisms and delivery modalities that influence adherence and resource utilization. Consequently, clinicians, payers, and manufacturers are re-evaluating care pathways, diagnostic workflows, and service models to optimize value for patients while managing constrained health system budgets.

The introduction of therapies that target different nodes of the complement cascade has also catalyzed new research directions and commercial strategies. As the field matures, real-world evidence and long-term safety data will be decisive in shaping prescribing patterns and formulary decisions. Therefore, a nuanced understanding of clinical profiles, administration trade-offs, and system-level implications is essential for any organization aiming to participate successfully in the PNH treatment landscape.

Detailed analysis of paradigm-shifting innovations in therapeutic mechanisms, delivery modalities, and care models reshaping PNH management across stakeholders

Over the past several years, the PNH treatment landscape has undergone transformative shifts driven by mechanistic innovation, route-of-administration diversification, and a stronger emphasis on patient-centric care. The arrival of therapies that inhibit complement activation at proximal and terminal targets has increased therapeutic choice, enabling clinicians to tailor approaches based on hemolysis control, transfusion dependence, thrombotic risk, and comorbidities. These scientific advances are complemented by delivery innovations, such as subcutaneous formulations, which reduce clinic burden and support self-administration models that improve convenience and adherence.

Concurrently, healthcare systems have accelerated adoption of home-based care pathways, leveraging home infusion and specialty pharmacy services to lower institutional resource utilization and improve patient experience. Payers and providers are increasingly demanding robust real-world outcomes and pharmacoeconomic data to justify formulary placements, driving manufacturers to invest in post-approval evidence generation and value demonstration. Additionally, the competitive environment is prompting lifecycle management strategies, including dosing interval optimization and patient support programs, to differentiate products beyond primary efficacy.

Finally, integration of diagnostics and longitudinal monitoring is enhancing therapeutic decision-making, with biomarkers and clinical metrics informing escalation or switching strategies. Together, these shifts are moving PNH care from episodic, hospital-centered interventions toward sustained, individualized management paradigms that emphasize long-term safety, sustained hemolysis control, and improved quality of life.

Assessment of how potential United States tariff shifts in 2025 could influence supply chains, manufacturing localization, pricing dynamics, and patient access for PNH therapies

Potential tariff actions and trade policy adjustments announced for 2025 create strategic variables that can influence availability, cost structures, and supply chain resilience for biologics and their active ingredients. If new duties affect imported raw materials, single-use components, or finished biologic products, manufacturers may experience upward pressure on production costs. Those cost dynamics can, in turn, influence contracting behavior with payers and providers, prompting renegotiations of pricing terms and potentially accelerating discussions around risk-sharing or outcome-based agreements.

In response to tariff-driven uncertainty, manufacturers and contract manufacturing organizations may accelerate localization initiatives, diversify sourcing across multiple regions, or scale domestic capacity to shield critical inputs from cross-border cost volatility. These shifts can improve long-term supply reliability but require capital investment and time to operationalize. Distribution partners and specialty pharmacies will need to reassess inventory strategies and procurement timelines to mitigate short-term disruptions, while hospitals and clinic systems may adjust formulary choices to maintain budget neutrality.

For patients, the principal risks relate to access and affordability. Payer responses may include narrower preferred product listings, increased utilization management, or expanded emphasis on biosimilar or lower-cost alternatives where available. To preserve patient access, manufacturers can expand patient support programs and collaborate with providers to maintain continuity of care through home infusion or specialty pharmacy services. Policymakers and industry leaders should therefore view tariff impacts through a multi-stakeholder lens, aligning supply chain resilience measures with patient access safeguards and evidence-generation commitments.

Strategic segmentation analysis revealing how drug class, administration route, distribution channel, care setting, therapy line, and age cohort drive differentiated clinical and commercial strategies

A granular segmentation framework reveals differential dynamics across drug classes, routes of administration, distribution channels, end user types, lines of therapy, and age groups that collectively shape commercial and clinical strategies. Within drug class, the market distinguishes between proximal complement inhibitors and terminal complement inhibitors; the former focuses on agents that interrupt activation upstream of C5, while the latter includes long-established C5-targeted monoclonal antibodies with distinct dosing intervals and infusion requirements. Clinicians weigh these mechanistic differences alongside individual patient characteristics to guide switching and escalation decisions.

Route of administration is another critical determinant, with intravenous therapies typically administered in clinic or infusion center settings, and subcutaneous options enabling self-administration or home-based care. Distribution channel choices intersect directly with administration modalities: home infusion services, hospital pharmacies, and specialty pharmacies each offer different trade-offs in terms of adherence support, reimbursement complexity, and operational overhead. End users including clinics, home care providers, and hospitals require tailored service and training models to deliver therapies safely and effectively, particularly when transitioning patients to home-based administration.

Line-of-therapy considerations influence initial prescribing behavior and subsequent treatment sequencing, with first-line and subsequent-line contexts presenting distinct evidence thresholds and payer expectations. Age group segmentation between adult and pediatric patients introduces further nuance, as pediatric care settings demand additional safety monitoring, dosing considerations, and long-term outcome data. Together, these intersecting segments inform targeted clinical development, differentiated commercial messaging, and customized support services that optimize uptake and sustained use across patient cohorts.

Comparative regional insights into regulatory expectations, payer dynamics, and care delivery models across the Americas, EMEA, and Asia-Pacific that affect PNH adoption

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement frameworks, and care delivery models, shaping how therapies are adopted and scaled. In the Americas, regulatory approvals and established specialty care networks facilitate relatively rapid uptake of new biologics, while payer negotiation tends to emphasize value demonstration and managed-access agreements. This region also shows growing utilization of home-based services and specialty pharmacy solutions that reduce institutional burden and enhance patient convenience, with concentrated centers of expertise supporting complex case management.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and cost-containment policies result in variable access timelines and formulary decisions. Countries with centralized health technology assessment processes often require robust comparative and economic evidence before broad adoption, incentivizing manufacturers to invest in region-specific real-world studies and health economic modeling. In contrast, certain markets within the region may adopt accelerated access pathways for high-need rare disease therapies, necessitating tailored pricing and distribution approaches.

The Asia-Pacific region reflects a mix of rapidly modernizing healthcare infrastructure and diverse payer maturity. Urban centers are increasingly capable of deploying advanced therapeutic delivery models, while broader geographic access challenges persist in less resourced areas. Manufacturers looking to expand presence here must navigate complex regulatory submissions, local manufacturing considerations, and partnership models to ensure sustainable supply and appropriate patient support services across national markets.

Insightful assessment of how company strategies in clinical differentiation, manufacturing resilience, and service partnerships determine competitive positioning in PNH therapeutics

Company strategies in the PNH space reflect differentiated priorities around clinical differentiation, delivery modality innovation, manufacturing scale, and downstream support services. Established developers of C5-directed therapies have leveraged long-term safety datasets and dosing interval optimization to maintain healthcare system confidence, while newer entrants focusing on proximal complement inhibition emphasize mechanistic advantages in hemolysis control and the convenience of subcutaneous administration. This divergence creates clear opportunities for platforms that can demonstrate superior patient-relevant outcomes or materially improved administration experiences.

Additionally, several companies are investing in manufacturing resilience and supply chain redundancy to mitigate disruption risk, particularly given the complexity of biologics production. Partnerships with specialty pharmacies and home infusion providers are increasingly central to commercialization plans, as they facilitate patient onboarding, adherence monitoring, and coordination with payers. Firms pursuing lifecycle management strategies are also developing patient support programs and digital adherence tools to enhance long-term retention and capture real-world effectiveness data.

Finally, competitive positioning is shaped by regulatory strategy and evidence generation. Organizations that proactively generate head-to-head, real-world, and long-term safety data can influence formulary decisions and prescribing norms. Strategic collaborations, whether through licensing, co-promotion, or manufacturing alliances, remain a pragmatic route to broaden access, optimize cost structures, and accelerate diffusion in complex global markets.

Concrete and integrated recommendations for developers and commercial leaders to accelerate adoption, de-risk launches, and protect patient access in the PNH treatment landscape

Industry leaders should prioritize integrated strategies that unite clinical development, supply chain resilience, and payer engagement to secure sustained adoption in the PNH space. Begin by aligning clinical programs to generate evidence that speaks directly to payer and clinician decision criteria, emphasizing comparative effectiveness, long-term safety, and patient-reported outcomes. Parallel investments in real-world evidence platforms will strengthen value propositions and shorten the feedback loop between clinical practice and formulary decision-making.

Operationally, companies should pursue manufacturing diversification and strategic partnerships with contract manufacturers and specialty pharmacies to reduce single-source risk and enable flexible supply responses. Embedding robust patient support services-including initiation assistance for home administration, adherence monitoring, and financial navigation-will protect continuity of care and maintain favorable real-world performance measures. Moreover, exploring innovative contracting models such as outcomes-based agreements can align incentives with payers and mitigate upfront reimbursement risks while showcasing long-term value.

Finally, leadership teams should invest in cross-functional launch readiness that integrates regulatory, medical affairs, market access, and commercial functions. Tailored education for prescribers and infusion centers, clear transitions to home care pathways, and proactive pediatric strategy development will collectively improve uptake and patient outcomes. These actionable steps create a resilient, patient-centered approach that balances innovation with practical delivery and payer realities.

Transparent explanation of the mixed-methods research approach combining stakeholder interviews, literature synthesis, and scenario analysis to underpin practical strategic conclusions

This analysis synthesizes primary and secondary research components to ensure comprehensive coverage of clinical, commercial, and policy dimensions. Primary inputs include structured interviews with clinical experts, payers, and operational leaders across infusion centers and specialty pharmacies, complemented by pharmaceutical company disclosures and regulatory documentation. Secondary research draws on peer-reviewed literature, clinical trial registries, and public regulatory decisions to contextualize therapeutic profiles, safety considerations, and label differentials.

Analytical methods incorporate comparative mechanism assessment, route-of-administration impact modeling on care delivery workflows, and scenario planning for policy variables such as trade measures and reimbursement shifts. Segmentation mapping evaluated how drug class, administration route, distribution channels, care settings, therapy line, and age cohort interact to influence adoption and service needs. The methodology also includes a qualitative synthesis of patient pathway implications and a risk assessment of supply chain vulnerabilities, with limitations clearly articulated where evidence is presently limited or evolving.

Triangulation across data sources and stakeholder perspectives strengthens the robustness of conclusions, while sensitivity analyses of key assumptions provide clarity on which variables most materially affect strategic choices. This layered approach ensures the report supports pragmatic decision-making for clinical development, market access planning, and operational execution in a rapidly changing therapeutic area.

Conclusive synthesis highlighting the essential strategic priorities required to convert therapeutic innovation into sustained patient access and system-aligned value

The current PNH therapeutic environment is characterized by meaningful clinical advances, evolving care delivery models, and intensifying commercial and policy complexities that together require agile and evidence-driven strategies. Mechanistic diversification in complement inhibition and the shift toward more patient-friendly administration modalities have improved clinical options, but they also demand coordinated approaches to evidence generation, payer negotiation, and service delivery redesign. Stakeholders that integrate clinical differentiation with operational excellence and payer-aligned value demonstration will be best positioned to succeed.

Practical imperatives include investing in real-world evidence to validate long-term outcomes, strengthening manufacturing and distribution resilience to protect access, and tailoring patient support services to sustain adherence and optimize real-world effectiveness. Regulatory heterogeneity across regions underscores the need for targeted market entry strategies and adaptive pricing approaches that respect local reimbursement norms. Collectively, these priorities form a roadmap for translating therapeutic innovation into sustainable access and improved patient outcomes.

In closing, the interplay of science, service, and systems thinking will determine which therapies achieve broad adoption and which operational models deliver scalable patient benefits. Stakeholders who act decisively to align clinical value with delivery feasibility and payer expectations will shape the next chapter of PNH care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for PNH Market, by Drug Class

  • 8.1. Proximal Complement Inhibitors
  • 8.2. Terminal Complement Inhibitors
    • 8.2.1. Eculizumab
    • 8.2.2. Ravulizumab

9. Drugs for PNH Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Subcutaneous

10. Drugs for PNH Market, by Distribution Channel

  • 10.1. Home Infusion
  • 10.2. Hospital Pharmacy
  • 10.3. Specialty Pharmacy

11. Drugs for PNH Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Drugs for PNH Market, by Line Of Therapy

  • 12.1. First-Line
  • 12.2. Subsequent-Line

13. Drugs for PNH Market, by Age Group

  • 13.1. Adult
  • 13.2. Pediatric
  • 13.3. Geriatric

14. Drugs for PNH Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drugs for PNH Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drugs for PNH Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Drugs for PNH Market

18. China Drugs for PNH Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Alexion Pharmaceuticals, Inc.
  • 19.7. Amgen Inc.
  • 19.8. Apellis Pharmaceuticals, Inc.
  • 19.9. AstraZeneca PLC
  • 19.10. Biogen Inc.
  • 19.11. Boehringer Ingelheim International GmbH
  • 19.12. Bristol Myers Squibb Company
  • 19.13. Catalyst Biosciences, Inc.
  • 19.14. Ionis Pharmaceuticals, Inc.
  • 19.15. Janssen Pharmaceuticals, Inc.
  • 19.16. Merck & Co., Inc.
  • 19.17. Novartis AG
  • 19.18. Pfizer Inc.
  • 19.19. Ra Pharmaceuticals
  • 19.20. Regeneron Pharmaceuticals, Inc.
  • 19.21. Roche Holding AG
  • 19.22. Sanofi
  • 19.23. Swedish Orphan Biovitrum AB
  • 19.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR PNH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR PNH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR PNH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUGS FOR PNH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS DRUGS FOR PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GCC DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. G7 DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. G7 DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. G7 DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. NATO DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. NATO DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. NATO DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)